Journal
JOURNAL OF LEUKOCYTE BIOLOGY
Volume 108, Issue 1, Pages 73-81Publisher
OXFORD UNIV PRESS
DOI: 10.1002/JLB.2MR0120-352RR
Keywords
AK002; antolimab; eosinophils; ligands; mast cells; Siglec; signaling
Categories
Funding
- National Institute of Allergy and Infectious Diseases [U19AI136443, U19AI070535, 107905120]
Ask authors/readers for more resources
Mast cells and eosinophils are innate immune cells involved in both acute and chronic inflammatory responses. Siglecs are a family of cell surface receptors that share sialic acid binding activity. Over the past 20 years, our knowledge of the expression and function of Siglecs on cells of the immune system and others has greatly expanded, as has our understanding of their signaling, ligands, and possible roles in disease pathophysiology. Because of this, Siglecs have garnered interest as potential drug targets using strategies ranging from biologics to ligand-directed nanoparticles. This mini-review will highlight the state of our knowledge regarding human eosinophil and mast cell Siglecs, their biology, what they recognize, tools developed for in vitro and preclinical experimentation, and the status of ongoing efforts to develop drugs that engage eosinophil and mast cell Siglecs for potential therapeutic benefit.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available